## CLAIMS

1. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,




（III）

wherein

$R_1$ is selected from H, $C_{1-3}$ alkyl and $C_{3-5}$ cycloalkyl, wherein the $C_{1-3}$ alkyl and $C_{3-5}$ cycloalkyl are optionally substituted by 1, 2 or 3 $R_a$;

$R_2$ and $R_3$ are each independently $C_{1-3}$ alkyl, wherein the $C_{1-3}$ alkyl is optionally substituted by 1, 2 or 3 $R_b$;

$R_4$ is selected from H, F, Cl, Br, I and $C_{1-3}$ alkyl, wherein the $C_{1-3}$ alkyl is optionally substituted by 1, 2 or 3 $R_c$;

$R_5$ is selected from F, Cl, Br, I and $C_{1-3}$ alkyl, wherein the $C_{1-3}$ alkyl is optionally substituted by 1, 2 or 3 $R_e$;

m is selected from 0, 1 and 2;

n is selected from 0, 1 and 2;

ring A is selected from pyrazolyl and tetrahydropyranyl, wherein the pyrazolyl and tetrahydropyranyl are optionally substituted by 1, 2 or 3 $R_d$;

$R_a$, $R_b$, $R_c$ and $R_e$ are each independently selected from D, F, Cl, Br, I, OH and $OCH_3$;

$R_d$ is selected from F, Cl, Br, I, $CH_3$ and $OCH_3$.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein $R_1$ is selected from H, $CH_3$, and cyclopropyl, wherein the $CH_3$ and cyclopropyl are optionally substituted by 1, 2, or 3 $R_a$.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein $R_1$ is selected from H, $CH_3$, $CHF_2$, $CD_3$, $CH_2CH_2OCH_3$ and cyclopropyl.

4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein $R_2$ and $R_3$ are each independently selected from $CH_3$ and $CH_2CH_3$, wherein the $CH_3$ and $CH_2CH_3$ are optionally substituted by 1, 2 or 3 $R_b$.

5. The compound or pharmaceutically acceptable salt thereof according to claim 4, wherein $R_2$ and $R_3$ are each independently $CH_3$.

6. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein $R_4$ is selected from H, F, Cl, Br, I and $CH_3$, wherein the $CH_3$ is optionally substituted by 1, 2 or 3 $R_c$.

7. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein $R_4$ is selected from H, F, Cl, Br, I and $CH_3$.

8. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein $R_5$ is selected from F, Cl, Br, I and $CH_3$, wherein the $CH_3$ is optionally substituted by 1, 2 or 3 $R_e$.

9. The compound or pharmaceutically acceptable salt thereof according to claim 8, wherein $R_5$ is selected from F, Cl, Br, I and $CH_3$.

10. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from ,  and , wherein the ,  and  are optionally substituted by 1, 2, or 3 $R_d$.

11. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein

ring A is selected from , ,  and .

12. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the structural moiety  is selected from ,  and .

13. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein the structural moiety  is selected from ,  and .

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-9, wherein the compound is selected from



（I-1）



（I-2）



（III-1）



（III-2），

wherein

$R_1$ is as defined in any one of claims 1-3;

$R_2$ and $R_3$ are as defined in any one of claims 1, 4 or 5;

$R_4$ is as defined in any one of claims 1, 6 or 7;

$R_5$ is as defined in any one of claims 1, 8 or 9;

m is as defined in claim 1.

15. A compound represented by the following formula or a pharmaceutically acceptable salt thereof,



.

16. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-15 in the manufacture of a medicament for treating cancer.

17. The use according to claim 16, wherein the cancer is solid tumor.

18. The use according to claim 16 or 17, wherein the cancer is melanoma, non-small cell lung cancer, or BRAFV600E mutant non-small cell lung cancer.

19. A medicament, comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-15.